Journal of nanobiotechnology

Kidney-targeted fat nanoparticles carrying ANXA2 may reduce kidney injury by blocking cell death through CHMP2A

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Annexin A2 (ANXA2) is upregulated after renal ischemia-reperfusion injury (IRI).

  • Renal ischemia-reperfusion injury is a significant complication after nephron-sparing surgery.
  • Current preventive strategies for renal IRI are limited.
  • The functional role of Annexin A2 in renal IRI is not well understood.
  • The therapeutic potential of Annexin A2 in the context of renal IRI remains unclear.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

0 of 12
authors report competing interests
12 report none
PubMed
No competing interests reported.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the mrna technology brief

issue #48
A new RNA polymerase makes self-amplifying vaccine production 9x easier
2 days ago7 studies
issue #47
Engineers used AI to design a self-destruct switch that kills virus-infected cells on command
1 week ago7 studies
issue #46
A simple ligand swap redirected liver-targeting nanoparticles to the lungs with 200-fold more mRNA delivery
2 weeks ago7 studies
issue #45
A $1 device delivers naked mRNA vaccines as effectively as lipid nanoparticles in mice and human skin
3 weeks ago7 studies
issue #44
Light-activated lipid nanoparticles spin their way out of cellular traps to boost cancer vaccine results
4 weeks ago7 studies
issue #43
A common antibiotic switches self-amplifying RNA vaccines on and off — with 10x range between states
5 weeks ago7 studies
issue #42
A single LNP dose achieved 49% liver gene editing in mice — without viral vectors
6 weeks ago7 studies
issue #41
Buffer choice affects mRNA vaccine performance by 40% after freeze-thaw cycles
7 weeks ago7 studies
issue #40
mRNA vaccine boosted cancer immunotherapy survival rates by 70-80% in mice
8 weeks ago7 studies
issue #39
Combo flu-COVID mRNA vaccine shows durable immunity through 6 months in adults 50+
9 weeks ago7 studies
explore the archive
See more issues from the mrna technology brief